Measuring Disease Activity in Psoriatic Arthritis
نویسندگان
چکیده
منابع مشابه
Measuring Disease Activity in Psoriatic Arthritis
Over the past decade, the assessment of the disease activity in psoriatic arthritis (PsA) has rapidly evolved in view of the need for valid, feasible, and reliable outcome measures that can be ideally employed in longitudinal cohorts, clinical trials, and clinical practice as well as the growing paradigm of tight disease control and treating to target in the management of PsA. This paper review...
متن کاملAssessment of disease activity in psoriatic arthritis.
Psoriatic arthritis (PsA) historically has been assessed according to disease activity measures borrowed from rheumatoid arthritis. However, more disease activity measures specific to PsA have been developed. This development is appropriate, as the disease is not confined to the joints but has multiple manifestations, in addition to skin and joints. Assessments of disease activity are unique to...
متن کاملPsoriasis, psoriatic arthritis, or psoriatic disease?
In this issue of The Journal, Madland, et al report results of a 2 week pilot study on a dietary supplementation with seal oil compared to soy oil in patients with psoriatic polyarthritis1. Despite its short duration, several results of this research are significant. Mainly, 4 weeks after the treatment, subjects taking seal oil dietary supplementation reported improvement in patient’s global as...
متن کاملUltrasonographic Enthesopathy and Disease Activity in Psoriatic Arthritis
BACKGROUND To our knowledge, the correlation between ultrasonographic enthesopathy and severity in psoriatic arthritis (PsA) has been done before. However, the correlation between ultrasonography of enthesopathy and the Psoriatic Arthritis Disease Activity Score (PASDAS) have not been done. AIM To compare the results of ultrasonographic enthesopathy of foot and PASDAS in PsA. MATERIALS AND ...
متن کاملThe assessment of disease activity and outcomes in psoriatic arthritis.
Psoriatic Arthritis (PsA) is a common condition that significantly impacts affected patients. The introduction of novel therapeutic agents for PsA has generated considerable interest in both clinical trials and in clinical care. Thus, there is a great need for standardized outcome measures to assess the activity of disease and the response to therapy. Because psoriasis is a heterogeneous and mu...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Rheumatology
سال: 2012
ISSN: 1687-9260,1687-9279
DOI: 10.1155/2012/839425